The Board of AstraZeneca is recommending to shareholders a Harmonised Listing Structure for the company’s ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO) and the New York Stock Exchange (NYSE). This requires upgrading AstraZeneca’s existing US equity listing by way of a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing US listing of AstraZeneca ADRs on Nasdaq.

“Today we set out our proposed harmonised listing structure which will support our long-term strategy for sustainable growth, while remaining headquartered in the UK and listed in London, Stockholm and New York. Enabling a global listing structure will allow us to reach a broader mix of global investors and will make it even more attractive for all our shareholders to have the opportunity to participate in AstraZeneca’s exciting future,” says Michel Demaré, Chair, AstraZeneca.

Following implementation, shareholders will be able to trade their interests in AstraZeneca ordinary shares across the LSE, STO and NYSE.

Related article

AstraZeneca plans to invest USD 50 billion in US manufacturing and R&D

This investment is expected to create tens of thousands of new jobs across the country states the company. 


The Harmonised Listing Structure will not change AstraZeneca’s current status as a UK listed, headquartered and tax resident company which will continue to be included in the FTSE 100 index and the OMX Stockholm 30 index, it states.